CSA Medical dba RejuvenAir has filed a notice of an exempt offering of securities to raise $71,158,453.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, CSA Medical dba RejuvenAir is raising up to $71,158,453.00 in new funding. Sources indicate that as part of senior management President, Wendelin Maners played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About CSA Medical dba RejuvenAir
CSA Medical, Inc. develops and manufactures the RejuvenAir System, a proprietary interventional liquid nitrogen spray cryotherapy system that utilizes software-driven dosimetry and specialty catheters to enable delivery of cryogen spray inside the airways to flash freeze and destroy damaged cells allowing for a rejuvenative pattern of healing. The RejuvenAir System is approved in the EU and under clinical investigation in the United States.
To learn more about CSA Medical dba RejuvenAir, visit http://www.rejuvenair.com/
CSA Medical dba RejuvenAir Linkedin Page: https://www.linkedin.com/company/csa-medical-inc/
Contact:
Wendelin Maners, President
781-538-4720
https://www.linkedin.com/in/wendelin-maners-5636706/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.